智翔金泰(688443.SH)：GR1803注射液纳入优先审评品种名单

Core Viewpoint - Zhixiang Jintai (688443.SH) announced that its product GR1803 injection has been included in the priority review list by the National Medical Products Administration, indicating a significant step forward in its development for treating adult patients with relapsed or refractory multiple myeloma [1] Group 1 - The product GR1803 is intended for adult patients who have previously undergone at least three lines of treatment, including one proteasome inhibitor, one immunomodulator, and one anti-CD38 monoclonal antibody [1]